• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

作者信息

Girardin François, Manuel Oriol, Marzolini Catia, Buclin Thierry

机构信息

Division of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.

Infectious Diseases Service and Transplantation Centre, Lausanne, Lausanne University Hospital, Faculty of Medicine, University of Lausanne, Lausanne, Switzerland.

出版信息

Clin Microbiol Infect. 2022 Aug;28(8):1044-1046. doi: 10.1016/j.cmi.2022.03.030. Epub 2022 Mar 28.

DOI:10.1016/j.cmi.2022.03.030
PMID:35358684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8958820/
Abstract
摘要

相似文献

1
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.评估与药代动力学增强剂发生药物相互作用的风险：以利托那韦增强型奈玛特韦预防重症 COVID-19 为例。
Clin Microbiol Infect. 2022 Aug;28(8):1044-1046. doi: 10.1016/j.cmi.2022.03.030. Epub 2022 Mar 28.
2
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择
Acta Med Indones. 2022 Oct;54(4):638-644.
3
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.口服抗病毒药物利托那韦-奈玛特韦和莫努匹韦在多发性骨髓瘤患者中的使用与 COVID-19 重症率低相关：一项单中心前瞻性研究。
Viruses. 2023 Mar 8;15(3):704. doi: 10.3390/v15030704.
4
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.莫努匹韦和奈玛特韦-利托那韦：口服冠状病毒病 2019 抗病毒药物。
Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180.
5
Nirmatrelvir Plus Ritonavir: First Approval.奈玛特韦片/利托那韦片：首次获批。
Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
6
Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.奈玛特韦和利托那韦在终末期肾病行间歇性血液透析的 COVID-19 患者中的药代动力学。
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0122922. doi: 10.1128/aac.01229-22. Epub 2022 Oct 26.
7
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).新冠病毒感染者中奈玛特韦/利托那韦药物相互作用的管理：法国药理学和治疗学学会（SFPT）指南。
Therapie. 2022 Sep-Oct;77(5):509-521. doi: 10.1016/j.therap.2022.03.005. Epub 2022 Apr 20.
8
Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.使用他克莫司的新冠患者接受奈玛特韦/利托那韦治疗：描述药物相互作用结果的病例系列
J Int Med Res. 2024 May;52(5):3000605241247705. doi: 10.1177/03000605241247705.
9
Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.尼马曲韦/利托那韦治疗 SARS-CoV-2 阳性肾移植受者 - 四例病例系列。
BMC Nephrol. 2023 Apr 15;24(1):99. doi: 10.1186/s12882-023-03154-w.
10
Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients.奈玛特韦/利托那韦作为免疫功能低下患者长期感染新型冠状病毒的潜在治疗方法。
Rev Esp Quimioter. 2022 Dec;35(6):589-591. doi: 10.37201/req/078.2022. Epub 2022 Oct 18.

引用本文的文献

1
Linking TLR-7 Signaling to Downregulation of Placental P-Glycoprotein: Implications for Fetal Drug Exposure.将Toll样受体7（TLR-7）信号传导与胎盘P-糖蛋白的下调联系起来：对胎儿药物暴露的影响。
Pharmaceutics. 2025 Jun 5;17(6):741. doi: 10.3390/pharmaceutics17060741.
2
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.帕罗韦德与CYP3A酶和P-糖蛋白转运体的药代动力学相互作用：临床数据概述
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
3
The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability.含奈玛特韦和利托那韦口服溶液的研发及其药代动力学和稳定性评估。
Pharmaceutics. 2024 Jan 14;16(1):109. doi: 10.3390/pharmaceutics16010109.
4
Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.来瑞特韦用于治疗未联用利托那韦的轻中度新型冠状病毒肺炎：一项多中心随机、双盲、安慰剂对照3期试验
EClinicalMedicine. 2023 Dec 14;67:102359. doi: 10.1016/j.eclinm.2023.102359. eCollection 2024 Jan.
5
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.SARS-CoV-2 对奈玛特韦耐药的分子机制。
Nature. 2023 Oct;622(7982):376-382. doi: 10.1038/s41586-023-06609-0. Epub 2023 Sep 11.
6
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics.尼马曲韦和 COVID-19：研发、药代动力学、临床疗效、耐药性、复发和药物经济学。
Int J Antimicrob Agents. 2023 Feb;61(2):106708. doi: 10.1016/j.ijantimicag.2022.106708. Epub 2023 Jan 2.